These data suggest that CMTM6 inhibition may alleviate trastuzumab resistance and promote the efficacy of anti-HER2 therapy, highlighting the need to develop small-molecule inhibitors of CMTM6 as potential therapeutic strategies for the treatment of trastuzumab-resistant HER2+ BC. Here, ERBB2 is linked to breast cancer.